GLP Watchdog

bmiMD vs Gala

Neither bmiMD nor Gala has an FDA warning letter on record. On compounded semaglutide injection, bmiMD costs $600 less a year at standing rates: $129 a month against $179 a month at Gala.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

bmiMD / Gala

bmiMD logo

bmiMD

8.2/10

Gala logo

Gala

8.5/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$129/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit bmiMD
Visit Gala

Both bmiMD and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (bmiMD 8.2, Gala 8.5). How we are paid

What the record shows

  1. 01

    Neither bmiMD nor Gala has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded semaglutide injection, bmiMD costs $600 less a year at standing rates: $129 a month against $179 a month at Gala.

  4. 04

    Only Gala lists a price for brand-name semaglutide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

bmiMD

Gala

Compounded semaglutide injection

$129/moLower

$1,548 a year

$179/mo

$2,148 a year

Compounded tirzepatide injection

$179/mo

$2,148 a year

$179/mo

$2,148 a year

Brand-name semaglutide pen
Not sold or not priced

$1,299/mo

$15,588 a year

Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on monthly plans; longer plans are paid in full at checkout
Yearly plan for the $179 rate; 72 hours' notice before the billing date to cancel
Refunds
Authorization hold released if not approved; $100 fee after intake; multi-month plans non-refundable
No refund on cancellation; full refund only if the medical provider disqualifies you

Read off each seller’s own pages. bmiMD: October 17, 2026. Gala: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for bmiMD

8.2/10
  • $600 a year less on compounded semaglutide injection
  • Names no compounding pharmacy
Visit bmiMD

The case for Gala

8.5/10
  • Sells brand-name semaglutide pen, which bmiMD does not price
  • Names no compounding pharmacy
Visit Gala

Scores

bmiMD 8.2 · Gala 8.5 out of 10. Six weighted parts.

Value25%

6.0A
vs
B
7.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

8.5A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

bmiMD vs Gala: questions

Neither bmiMD nor Gala has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
bmiMD, by $600 a year at standing rates. bmiMD: $129 a month, about $1,548 a year. Gala: $179 a month, about $2,148 a year.
bmiMD states you can cancel at any time; refunds: authorization hold released if not approved; $100 fee after intake; multi-month plans non-refundable. Gala states you can cancel at any time; refunds: no refund on cancellation; full refund only if the medical provider disqualifies you.
Both bmiMD and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (bmiMD 8.2, Gala 8.5).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks